Balance Sheet Insmed Incorporated

Stocks

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2026 am IST			After hours 02:04:15 am
107.46 ^USD	-2.14%		106.36	-1.03%

05:36pm	Insmed Announces Positive 12-Month Data From Ongoing Open-Label Extension Study Of Treprostinil Palmitil Inhalation Powder In Patients With Pulmonary Arterial Hypertension	CI
05:12pm	Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients	MT

a54f45b04df19118459.8nfzmiMK79Wya6b4-npCQ7wSu9W8GZegh1-RyLhg7do.mUDC0E5MrofeP8PPsQM6d9NY1rDEQd3qszPLkoAutYmUTp7sSSfWpeUs5w

Published financial data: INSMED INCORPORATED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	19Cr	25Cr	31Cr	36Cr	61Cr
Total Revenues	19Cr	25Cr	31Cr	36Cr	61Cr
Cost of Goods Sold, Total	4.42Cr	5.51Cr	6.56Cr	8.57Cr	12Cr
Gross Profit	14Cr	19Cr	24Cr	28Cr	48Cr
Selling General & Admin Expenses, Total	23Cr	27Cr	34Cr	46Cr	70Cr
R&D Expenses	27Cr	40Cr	57Cr	60Cr	77Cr
Amortization of Goodwill and Intangible Assets - (IS)	50.52L	50.53L	50.52L	50.52L	60.01L
Other Operating Expenses, Total	51Cr	67Cr	92Cr	106.45Cr	147.83Cr
Operating Income	-37Cr	-48Cr	-68Cr	-79Cr	-99Cr
Interest Expense, Total	-4.05Cr	-2.8Cr	-8.14Cr	-8.51Cr	-8.38Cr
Interest And Investment Income	2L	1.11Cr	4.21Cr	5.33Cr	6.07Cr
Net Interest Expenses	-4.03Cr	-1.69Cr	-3.92Cr	-3.18Cr	-2.31Cr
Other Non Operating Income (Expenses)	-33.3L	-59.39L	18.56L	29T	-18.41L
EBT, Excl. Unusual Items	-41Cr	-50Cr	-72Cr	-82Cr	-101.98Cr
Merger & Related Restructuring Charges	-6L	-	-	-	-
Other Unusual Items	-2.5Cr	2.08Cr	-2.87Cr	-9.17Cr	-25Cr
EBT, Incl. Unusual Items	-44Cr	-48Cr	-75Cr	-91Cr	-127.17Cr
Income Tax Expense	-17.58L	13.83L	25.55L	37.07L	50.26L
Earnings From Continuing Operations	-43Cr	-48Cr	-75Cr	-91Cr	-127.68Cr
Net Income to Company	-43Cr	-48Cr	-75Cr	-91Cr	-127.68Cr
Net Income - (IS)	-43Cr	-48Cr	-75Cr	-91Cr	-127.68Cr
Net Income to Common Incl Extra Items	-43Cr	-48Cr	-75Cr	-91Cr	-127.68Cr
Net Income to Common Excl. Extra Items	-43Cr	-48Cr	-75Cr	-91Cr	-127.68Cr
Per Share Items
Net EPS - Basic	-3.88	-3.91	-5.34	-5.57	-6.42
Basic EPS - Continuing Operations	-3.88	-3.91	-5.34	-5.57	-6.42
Basic Weighted Average Shares Outstanding	11Cr	12Cr	14Cr	16Cr	20Cr
Net EPS - Diluted	-3.88	-3.91	-5.34	-5.57	-6.42
Diluted EPS - Continuing Operations	-3.88	-3.91	-5.34	-5.57	-6.42
Diluted Weighted Average Shares Outstanding	11Cr	12Cr	14Cr	16Cr	20Cr
Normalized Basic EPS	-2.29	-2.54	-3.2	-3.12	-3.2
Normalized Diluted EPS	-2.29	-2.54	-3.2	-3.12	-3.2
Supplemental Items
EBITDA	-36Cr	-47Cr	-67Cr	-78Cr	-98Cr
EBITA	-37Cr	-48Cr	-68Cr	-79Cr	-99Cr
EBIT	-37Cr	-48Cr	-68Cr	-79Cr	-99Cr
EBITDAR	-34Cr	-45Cr	-65Cr	-74Cr	-94Cr
Effective Tax Rate - (Ratio)	0.4	-0.29	-0.34	-0.41	-0.4
Current Domestic Taxes	1L	3L	4L	4L	6L
Current Foreign Taxes	15.85L	13.45L	22.31L	33.8L	44.76L
Total Current Taxes	16.89L	16.14L	26.09L	37.36L	50.53L
Deferred Domestic Taxes	-34.47L	-2L	-54T	-29T	-27T
Total Deferred Taxes	-34.47L	-2L	-54T	-29T	-27T
Normalized Net Income	-26Cr	-31Cr	-45Cr	-51Cr	-64Cr
Interest on Long-Term Debt	4.05Cr	2.64Cr	8.17Cr	8.49Cr	8.38Cr
Supplemental Operating Expense Items
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	28Cr	40Cr	58Cr	60Cr	78Cr
Net Rental Expense, Total	1.92Cr	2.42Cr	2.45Cr	3.62Cr	3.56Cr
Imputed Operating Lease Interest Expense	1.22Cr	55.82L	1.19Cr	1.85Cr	2.32Cr
Imputed Operating Lease Depreciation	69.64L	1.86Cr	1.26Cr	1.77Cr	1.24Cr
Stock-Based Comp., R&D Exp. (Total)	1.78Cr	2.64Cr	3.59Cr	4.77Cr	7Cr
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	2.82Cr	3.13Cr	3.89Cr	4.92Cr	8.27Cr
Stock-Based Comp., Other (Total)	13L	13L	-	-	-
Total Stock-Based Compensation	4.73Cr	5.9Cr	7.48Cr	9.68Cr	15Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	72Cr	107.4Cr	48Cr	56Cr	51Cr
Short Term Investments	-	7.42Cr	30Cr	88Cr	92Cr
Total Cash And Short Term Investments	72Cr	114.83Cr	78Cr	143.38Cr	143Cr
Accounts Receivable, Total	2.44Cr	2.97Cr	4.12Cr	5.2Cr	14Cr
Total Receivables	2.44Cr	2.97Cr	4.12Cr	5.2Cr	14Cr
Inventory	6.7Cr	6.99Cr	8.32Cr	9.86Cr	13Cr
Prepaid Expenses	2.89Cr	2.55Cr	2.42Cr	3.72Cr	9.12Cr
Total Current Assets	84Cr	127.34Cr	93Cr	162.17Cr	179.42Cr
Gross Property Plant And Equipment	13Cr	14Cr	15Cr	17Cr	20Cr
Accumulated Depreciation	-3.71Cr	-3.94Cr	-4.46Cr	-5.03Cr	-6.08Cr
Net Property Plant And Equipment	9.55Cr	10Cr	10Cr	12Cr	14Cr
Long-term Investments	5Cr	-	-	-	-
Goodwill	14Cr	14Cr	14Cr	14Cr	14Cr
Other Intangibles, Total	3.14Cr	3.12Cr	3.1Cr	3.08Cr	7.46Cr
Deferred Charges Long-Term	4.24Cr	3.76Cr	3.27Cr	2.79Cr	2.3Cr
Other Long-Term Assets, Total	5.1Cr	7.61Cr	9.66Cr	9.32Cr	9.74Cr
Total Assets	124.35Cr	165.64Cr	132.98Cr	202.52Cr	226.46Cr
Liabilities
Accounts Payable, Total	3.58Cr	5.05Cr	6.54Cr	7.3Cr	7.99Cr
Accrued Expenses, Total	8.38Cr	11Cr	13Cr	18Cr	30Cr
Current Portion of Leases	1.01Cr	81.26L	1.06Cr	1.23Cr	1.28Cr
Other Current Liabilities	54.34L	2.36Cr	2.14Cr	3.07Cr	7.28Cr
Total Current Liabilities	14Cr	19Cr	23Cr	30Cr	47Cr
Long-Term Debt	57Cr	127.33Cr	131.03Cr	126.44Cr	70Cr
Long-Term Leases	3.55Cr	4.45Cr	3.8Cr	3.32Cr	3.29Cr
Other Non Current Liabilities	9.57Cr	6.05Cr	8.77Cr	14Cr	32Cr
Total Liabilities	83Cr	156.85Cr	166.18Cr	173.99Cr	152.56Cr
Common Stock, Total	11.87L	13.57L	14.8L	17.94L	21.43L
Additional Paid In Capital	267.36Cr	278.24Cr	311.35Cr	464.58Cr	637.21Cr
Retained Earnings	-226.52Cr	-269.66Cr	-344.61Cr	-435.99Cr	-563.67Cr
Comprehensive Income and Other	10L	8L	-7L	-22.89L	14.61L
Total Common Equity	41Cr	8.8Cr	-33Cr	29Cr	74Cr
Total Equity	41Cr	8.8Cr	-33Cr	29Cr	74Cr
Total Liabilities And Equity	124.35Cr	165.64Cr	132.98Cr	202.52Cr	226.46Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	12Cr	14Cr	15Cr	18Cr	22Cr
ECS Total Common Shares Outstanding	12Cr	14Cr	15Cr	18Cr	21Cr
Book Value / Share	3.46	0.65	-2.24	1.59	3.45
Tangible Book Value	24Cr	-7.93Cr	-50Cr	12Cr	53Cr
Tangible Book Value Per Share	2.05	-0.58	-3.37	0.66	2.47
Total Debt	61Cr	132.59Cr	135.9Cr	130.99Cr	75Cr
Net Debt	-15Cr	18Cr	58Cr	-12Cr	-68Cr
Debt Equivalent Oper. Leases	15Cr	19Cr	20Cr	29Cr	29Cr
Account Code - Inventory Valuation	3	3	5	5	5
Inventories - Raw Materials, Total	2.95Cr	2.72Cr	2.46Cr	1.97Cr	3.06Cr
Inventories - Work In Process, Total	1.85Cr	2.25Cr	3.35Cr	3.99Cr	4.13Cr
Inventories - Finished Goods, Total	1.89Cr	2.02Cr	2.52Cr	3.9Cr	6.01Cr
Land - (BS)	-	-	-	-	19.63L
Buildings, Total	-	-	-	-	1.04Cr
Machinery, Total	2.62Cr	2.94Cr	3.65Cr	4.12Cr	5.55Cr
Full Time Employees	613	736	912	1.27T	1.66T

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-43Cr	-48Cr	-75Cr	-91Cr	-127.68Cr
Depreciation & Amortization - CF	1.02Cr	72.38L	82.39L	86.73L	1.32Cr
Amortization of Goodwill and Intangible Assets - (CF)	2L	2L	2L	2L	11.51L
Depreciation & Amortization, Total	1.04Cr	74.4L	84.41L	88.75L	1.43Cr
Amortization of Deferred Charges, Total - (CF)	3.59Cr	88.42L	1.22Cr	1.17Cr	1.11Cr
(Gain) Loss on Sale of Investments - (CF)	-	15.26L	-97.03L	-1.89Cr	-3.83Cr
Stock-Based Compensation (CF)	4.6Cr	5.77Cr	7.48Cr	9.68Cr	15Cr
Other Operating Activities, Total	3.76Cr	-10L	17Cr	13Cr	28Cr
Change In Accounts Receivable	-81.18L	-64.23L	-1.2Cr	-1.29Cr	-8.83Cr
Change In Inventories	-1.75Cr	-17.14L	-1.36Cr	-1.7Cr	-3.15Cr
Change In Accounts Payable	-75.75L	5Cr	1.52Cr	4.46Cr	10Cr
Change in Other Net Operating Assets	-2.54Cr	-3.53Cr	-2.88Cr	-1.78Cr	-6.05Cr
Cash from Operations	-36Cr	-40Cr	-54Cr	-68Cr	-94Cr
Capital Expenditure	-72.89L	-98.78L	-1.33Cr	-2.19Cr	-3.26Cr
Cash Acquisitions	-67.04L	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-	-3Cr
Investment in Marketable and Equity Securities, Total	-5.03Cr	-2.47Cr	-21Cr	-56Cr	-20.14L
Other Investing Activities, Total	-	-	34.17L	-	-
Cash from Investing	-6.43Cr	-3.46Cr	-22Cr	-58Cr	-6.46Cr
Long-Term Debt Issued, Total	58Cr	50Cr	-	15Cr	-
Total Debt Issued	58Cr	50Cr	-	15Cr	-
Long-Term Debt Repaid, Total	-22Cr	-	-12.17L	-26.1L	-49.26L
Total Debt Repaid	-22Cr	-	-12.17L	-26.1L	-49.26L
Issuance of Common Stock	29Cr	31Cr	17Cr	119.74Cr	96Cr
Other Financing Activities, Total	-2.94Cr	-1.84Cr	-12.18L	-37.37L	-
Cash from Financing	61Cr	79Cr	17Cr	134.1Cr	95Cr
Foreign Exchange Rate Adjustments	-9L	-10L	-2L	-13.07L	9L
Net Change in Cash	18Cr	36Cr	-59Cr	7.27Cr	-4.46Cr
Supplemental Items
Cash Interest Paid	1.09Cr	1.02Cr	3.58Cr	4.06Cr	5.54Cr
Cash Income Tax Paid (Refund)	15.58L	17.17L	19.55L	24.99L	41.41L
Levered Free Cash Flow	-18Cr	-20Cr	-38Cr	-42Cr	-56Cr
Unlevered Free Cash Flow	-19Cr	-19Cr	-34Cr	-37Cr	-52Cr
Change In Net Working Capital	1.13Cr	-5.22Cr	-93.57L	-3.1Cr	54.75L
Net Debt Issued / Repaid	35Cr	50Cr	-12.17L	15Cr	-49.26L

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-22.5	-20.61	-28.5	-29.31	-28.99
Return on Total Capital	-26.94	-24.53	-34.87	-37.49	-40.32
Return On Equity %	-126.66	-193.22	614.47	3.93T	-249.28
Return on Common Equity	-126.66	-193.22	614.47	3.93T	-249.28
Margin Analysis
Gross Profit Margin %	76.57	77.53	78.52	76.43	79.73
SG&A Margin	123.99	108.32	112.87	126.78	115.62
EBITDA Margin %	-189.3	-191.84	-220.34	-213.82	-161.68
EBITA Margin %	-194.71	-194.79	-223.04	-216.21	-163.85
EBIT Margin %	-194.82	-194.87	-223.1	-216.26	-164.04
Income From Continuing Operations Margin %	-230.63	-196.26	-245.59	-251.24	-210.54
Net Income Margin %	-230.63	-196.26	-245.59	-251.24	-210.54
Net Avail. For Common Margin %	-230.63	-196.26	-245.59	-251.24	-210.54
Normalized Net Income Margin	-136.23	-127.61	-147.1	-140.63	-105.1
Levered Free Cash Flow Margin	-95.4	-80.97	-126.14	-115.01	-93.01
Unlevered Free Cash Flow Margin	-98.44	-75.48	-111.87	-102.27	-85.4
Asset Turnover
Asset Turnover	0.18	0.17	0.2	0.22	0.28
Fixed Assets Turnover	1.96	2.48	2.96	3.31	4.76
Receivables Turnover (Average Receivables)	9.21	9.08	8.61	7.8	6.29
Inventory Turnover (Average Inventory)	0.76	0.81	0.86	0.94	1.07
Short Term Liquidity
Current Ratio	6.19	6.69	4.12	5.45	3.83
Quick Ratio	5.48	6.19	3.64	4.99	3.35
Operating Cash Flow to Current Liabilities	-2.69	-2.1	-2.38	-2.3	-1.99
Days Sales Outstanding (Average Receivables)	39.62	40.21	42.4	46.89	58.04
Days Outstanding Inventory (Average Inventory)	481.96	453.32	426.3	388.07	342.39
Average Days Payable Outstanding	233.09	271.19	267.98	250.63	178.43
Cash Conversion Cycle (Average Days)	288.49	222.34	200.71	184.33	222
Long Term Solvency
Total Debt/Equity	149.16	1.51T	-409.44	459.02	101.43
Total Debt / Total Capital	59.87	93.78	132.32	82.11	50.35
LT Debt/Equity	146.69	1.5T	-406.23	454.7	99.69
Long-Term Debt / Total Capital	58.87	93.2	131.28	81.34	49.49
Total Liabilities / Total Assets	66.99	94.69	124.96	85.91	67.37
EBIT / Interest Expense	-9.07	-17.09	-8.37	-9.24	-11.87
EBITDA / Interest Expense	-8.34	-15.96	-7.96	-8.71	-11.28
(EBITDA - Capex) / Interest Expense	-8.52	-16.32	-8.13	-8.97	-11.66
Total Debt / EBITDA	-1.81	-2.97	-2.1	-1.77	-0.79
Net Debt / EBITDA	0.46	-0.4	-0.89	0.17	0.72
Total Debt / (EBITDA - Capex)	-1.78	-2.91	-2.06	-1.72	-0.77
Net Debt / (EBITDA - Capex)	0.45	-0.39	-0.87	0.16	0.7
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	14.63	30.19	24.39	19.17	66.73
Gross Profit, 1 Yr. Growth %	15.87	31.82	25.97	16	73.94
EBITDA, 1 Yr. Growth %	39.98	31.94	42.87	15.64	26.07
EBITA, 1 Yr. Growth %	38.43	30.24	42.44	15.52	26.36
EBIT, 1 Yr. Growth %	38.43	30.22	42.42	15.51	26.47
Earnings From Cont. Operations, 1 Yr. Growth %	47.8	10.79	55.66	21.91	39.73
Net Income, 1 Yr. Growth %	47.8	10.79	55.66	21.91	39.73
Normalized Net Income, 1 Yr. Growth %	40.35	21.95	43.39	13.93	24.61
Diluted EPS Before Extra, 1 Yr. Growth %	28.77	0.87	36.44	4.31	15.25
Accounts Receivable, 1 Yr. Growth %	47.03	22.02	38.62	26.28	170.82
Inventory, 1 Yr. Growth %	35.12	4.35	19.06	18.41	33.97
Net Property, Plant and Equip., 1 Yr. Growth %	-1.77	6.87	2.26	10.73	20.44
Total Assets, 1 Yr. Growth %	56.19	33.21	-19.72	52.29	11.82
Tangible Book Value, 1 Yr. Growth %	-11.29	-132.65	529.04	-123.75	345.76
Common Equity, 1 Yr. Growth %	48.78	-78.57	-477.4	-185.98	158.95
Cash From Operations, 1 Yr. Growth %	65.63	10.22	33.91	27.53	36.72
Capital Expenditures, 1 Yr. Growth %	16.81	35.52	34.52	64.98	48.52
Levered Free Cash Flow, 1 Yr. Growth %	67.7	10.51	92.51	8.65	34.84
Unlevered Free Cash Flow, 1 Yr. Growth %	70.05	-0.18	83.09	8.94	39.23
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	17.52	22.16	27.26	21.75	40.96
Gross Profit, 2 Yr. CAGR %	13.38	23.59	28.86	20.88	42.04
EBITDA, 2 Yr. CAGR %	26	37.21	38.24	29.21	21.18
EBITA, 2 Yr. CAGR %	26.24	35.52	37.11	28.93	21.25
EBIT, 2 Yr. CAGR %	24.93	34.26	36.18	28.26	20.87
Earnings From Cont. Operations, 2 Yr. CAGR %	30.73	27.96	31.32	37.75	30.51
Net Income, 2 Yr. CAGR %	30.73	27.96	31.32	37.75	30.51
Normalized Net Income, 2 Yr. CAGR %	27.28	30.83	32.24	27.81	19.15
Diluted EPS Before Extra, 2 Yr. CAGR %	13.54	13.97	17.32	19.3	9.65
Accounts Receivable, 2 Yr. CAGR %	12.52	33.94	30.06	32.31	84.93
Inventory, 2 Yr. CAGR %	53.84	18.74	11.46	18.74	25.95
Net Property, Plant and Equip., 2 Yr. CAGR %	-8.11	2.46	4.54	6.41	15.48
Total Assets, 2 Yr. CAGR %	29.43	44.24	3.41	10.57	30.49
Tangible Book Value, 2 Yr. CAGR %	-3.35	-46.18	43.3	22.22	2.89
Common Equity, 2 Yr. CAGR %	25.24	-43.54	-10.08	80.13	49.21
Cash From Operations, 2 Yr. CAGR %	20.39	35.11	21.49	30.68	32.05
Capital Expenditures, 2 Yr. CAGR %	-58.47	25.82	35.02	48.98	56.54
Levered Free Cash Flow, 2 Yr. CAGR %	-4.89	36.16	45.81	44.63	21.04
Unlevered Free Cash Flow, 2 Yr. CAGR %	-3.88	30.31	35.19	41.23	23.16
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	167.6	21.6	22.9	24.5	35.2
Gross Profit, 3 Yr. CAGR %	169.02	19.22	24.38	24.42	36.47
EBITDA, 3 Yr. CAGR %	5.65	27.95	39.07	30.26	28.15
EBITA, 3 Yr. CAGR %	6.23	27.56	37.79	29.5	28.07
EBIT, 3 Yr. CAGR %	6.11	26.67	36.93	28.91	27.66
Earnings From Cont. Operations, 3 Yr. CAGR %	10.26	23.71	36.6	28.1	38.41
Net Income, 3 Yr. CAGR %	10.26	23.71	36.6	28.1	38.41
Normalized Net Income, 3 Yr. CAGR %	8.47	25.48	34.89	25.83	26.74
Diluted EPS Before Extra, 3 Yr. CAGR %	-2.76	9.15	21.02	12.81	17.94
Accounts Receivable, 3 Yr. CAGR %	64.06	15.6	35.48	28.78	67.99
Inventory, 3 Yr. CAGR %	112.01	35.17	18.85	13.73	23.61
Net Property, Plant and Equip., 3 Yr. CAGR %	61.59	-3.36	2.39	6.56	10.89
Total Assets, 3 Yr. CAGR %	27.18	30.68	18.65	17.65	10.99
Tangible Book Value, 3 Yr. CAGR %	5.56	-32.69	22.13	-21.29	88.14
Common Equity, 3 Yr. CAGR %	25.38	-30.47	6.36	-11.41	103.3
Cash From Operations, 3 Yr. CAGR %	12.09	16.9	34.71	23.47	32.67
Capital Expenditures, 3 Yr. CAGR %	-17.73	-38.4	28.65	44.35	48.83
Levered Free Cash Flow, 3 Yr. CAGR %	5.28	-0.01	53.16	32.19	41.29
Unlevered Free Cash Flow, 3 Yr. CAGR %	6.07	-2.66	46.29	25.8	40.56
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	98.78	21.66	29.83
Gross Profit, 5 Yr. CAGR %	10.58	-	100.41	19.88	31.16
EBITDA, 5 Yr. CAGR %	15.85	20.4	17.32	28.19	31.43
EBITA, 5 Yr. CAGR %	16.18	20.4	17.33	27.85	30.73
EBIT, 5 Yr. CAGR %	16.19	20.41	17.25	27.3	30.26
Earnings From Cont. Operations, 5 Yr. CAGR %	19.78	20.11	18.24	29.15	34.13
Net Income, 5 Yr. CAGR %	19.78	20.11	18.24	29.15	34.13
Normalized Net Income, 5 Yr. CAGR %	18.45	21.03	17.42	26.41	28.36
Diluted EPS Before Extra, 5 Yr. CAGR %	6.36	6.23	4.82	13.1	16.33
Accounts Receivable, 5 Yr. CAGR %	-	-	49.5	22.02	53.44
Inventory, 5 Yr. CAGR %	-	-	63.93	28.34	21.64
Net Property, Plant and Equip., 5 Yr. CAGR %	56.98	52.36	35.76	0.43	7.44
Total Assets, 5 Yr. CAGR %	39.2	29.09	17.08	22.23	23.25
Tangible Book Value, 5 Yr. CAGR %	9.48	-26.15	19.29	-14.55	14.04
Common Equity, 5 Yr. CAGR %	21.58	-24.61	9.77	1.75	21.78
Cash From Operations, 5 Yr. CAGR %	19.88	20.2	15.76	22.23	33.64
Capital Expenditures, 5 Yr. CAGR %	11.66	26.91	0.3	-12.3	39.16
Levered Free Cash Flow, 5 Yr. CAGR %	15.96	17.48	20.1	16.05	39.4
Unlevered Free Cash Flow, 5 Yr. CAGR %	17.22	16.61	17.04	13.12	36.56